Intergroup Corporation INTG Restricted Cash Equivalents in Other Assets

Restricted Cash Equivalents in Other Assets at other companies

James River Group Holdings, Inc. JRVR

$8.56M-70.5%

Agilon HealthAGL

$71.58M+4,156%

Achieve Life SciencesACHV

$52K+33.3%

Amylyx Pharmaceuticals, Inc.AMLX

$986K-32.0%

Vor BiopharmaVOR

$168K-93.0%

Liberty Broadband CorporationLBRDK

$57M-57.8%

Other financials

Income statement

See full

Revenue$20.4M+21.1%

Operating income$4.3M+81.3%

Net income$457.0K+179%

EPS (diluted)$0.21+178%

Balance sheet

See full

Cash & equivalents$9.3M+185,560%

Total debt$351.3M+37.8%

Total equity-$84.7M-0.3%

Total assets$103.5M+0.3%

Cash flow

See full

Operating cash flow$3.0M—

CapEx$354.0K+19.2%

Free cash flow$2.6M—

Valuation

See full

Market cap$103.19M+265%

Enterprise value$445.24M+57.6%

P/S1.4×+1.0×

Profitability

See full

Gross margin89.6%—

Operating margin14.4%+3.3pp

Net margin-0.3%-0.1pp

FCF margin5.2%—

Returns & leverage

See full

Return on equity0.3%—

Debt / equity-4.1×—

Where this comes from

Reported directly by Intergroup Corporation in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashEquivalents.

The official record: Intergroup Corporation’s 10-K, filed September 30, 2025, on SEC EDGAR. View the filing →

Ask your AI about Intergroup Corporation's restricted cash equivalents in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Intergroup Corporation's restricted cash equivalents in other assets?: Intergroup Corporation (INTG) reported restricted cash equivalents in other assets of $10.1M in Q2 2025.